ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.750,92
-0,31%
S&P 500
5.308,13
0,09%
US Dollar vs BRL
5,1041
-0,01%
Bitcoin
71.118,66
-0,46%
Brent Oil
82,345
-1,42%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Cynapsus Therapeutics Inc. (MM) (CYNA)

  7. Cynapsus Therapeutics Inc. (MM) (CYNA) Notícias

CYNA

Cynapsus Therapeutics Inc. (CYNA)

Cynapsus Therapeutics Inc. (MM)
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CYNA
DataHoraFonteTítuloCódigoCompanhia
04/05/202209:05Business WireCyngn Launches Infinitracker – A GPS Asset Tracker and IoT Gateway with 15-year BatteryNASDAQ:CYNACynapsus Therapeutics Inc. (MM)
02/05/202209:05Business WireCyngn Schedules 2022 First Quarter Financial Results Release and Conference CallNASDAQ:CYNACynapsus Therapeutics Inc. (MM)
29/04/202217:20Business WireCyngn Announces Closing of $20 Million Private Placement Priced At-the-MarketNASDAQ:CYNACynapsus Therapeutics Inc. (MM)
28/04/202210:15Business WireCyngn Announces Pricing of $20 Million Private Placement Priced At-the-MarketNASDAQ:CYNACynapsus Therapeutics Inc. (MM)
21/04/202209:30Business WireCyngn Launches DriveMod Kit, a Fully-Equipped Autonomous Vehicle Hardware Integration ModuleNASDAQ:CYNACynapsus Therapeutics Inc. (MM)
23/03/202217:05Business WireCyngn Reports Fourth Quarter and Year-end 2021 ResultsNASDAQ:CYNACynapsus Therapeutics Inc. (MM)
14/03/202209:05Business WireCyngn Schedules 2021 Fourth Quarter and Year-End Financial Results Release and Conference CallNASDAQ:CYNACynapsus Therapeutics Inc. (MM)
23/02/202210:05Business WireCyngn to Present at the Cowen 2nd Annual Mobility Disruption ConferenceNASDAQ:CYNACynapsus Therapeutics Inc. (MM)
15/02/202210:05Business WireCyngn Files Patent for DriveMod Kit, an Adaptive, Turnkey Autonomous Vehicle SolutionNASDAQ:CYNACynapsus Therapeutics Inc. (MM)
10/02/202210:05Business WireCyngn to Present at the Aegis Virtual ConferenceNASDAQ:CYNACynapsus Therapeutics Inc. (MM)
03/02/202210:00Business WireGreenland Technologies Chooses Cyngn to Bring Autonomous Vehicle Technology to Their Fleet of Lithium-Powered Electric ForkliftsNASDAQ:CYNACynapsus Therapeutics Inc. (MM)
24/01/202210:05Business WireCyngn Announces Appointment of HR Veteran Marc Brown as Vice President of Human ResourcesNASDAQ:CYNACynapsus Therapeutics Inc. (MM)
18/01/202210:05Business Wire Cyngn and Columbia Vehicle Group to Begin Building Fleet of Autonomous Industrial VehiclesNASDAQ:CYNACynapsus Therapeutics Inc. (MM)
10/01/202210:05Business WireGlobal Logistics & Fulfillment Taps Cyngn to Bring Autonomous Vehicle Capabilities to its Fulfillment CentersNASDAQ:CYNACynapsus Therapeutics Inc. (MM)
08/12/202110:05Business WireCyngn to Provide an Insider’s Look into the Company’s Technology Stack in its First Webinar on December 15, 2021NASDAQ:CYNACynapsus Therapeutics Inc. (MM)
17/11/202118:05Business WireCyngn Reports Third Quarter 2021 ResultsNASDAQ:CYNACynapsus Therapeutics Inc. (MM)
09/11/202110:30Business WireCyngn Schedules 2021 Third Quarter Financial Results Release and Conference CallNASDAQ:CYNACynapsus Therapeutics Inc. (MM)
22/10/202113:10Business WireCyngn Announces Closing of Initial Public OfferingNASDAQ:CYNACynapsus Therapeutics Inc. (MM)
19/10/202118:31Business WireCyngn Announces Pricing of Initial Public OfferingNASDAQ:CYNACynapsus Therapeutics Inc. (MM)
17/03/202017:23Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:CYNACynapsus Therapeutics Inc. (MM)
15/02/201710:09Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CYNACynapsus Therapeutics Inc. (MM)
01/11/201615:25Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(b) (15-12b)NASDAQ:CYNACynapsus Therapeutics Inc. (MM)
24/10/201619:00Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CYNACynapsus Therapeutics Inc. (MM)
21/10/201619:14Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:CYNACynapsus Therapeutics Inc. (MM)
21/10/201619:14Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:CYNACynapsus Therapeutics Inc. (MM)
21/10/201611:22Edgar (US Regulatory)(25-NSE)NASDAQ:CYNACynapsus Therapeutics Inc. (MM)
18/10/201611:08GlobeNewswire Inc.Cynapsus Therapeutics Obtains Final Court Order and HSR Waiting Period Expires for Plan of Arrangement with Sunovion Pharmace...NASDAQ:CYNACynapsus Therapeutics Inc. (MM)
13/10/201617:00GlobeNewswire Inc.Cynapsus Therapeutics Securityholders Approve the Plan of Arrangement with Sunovion PharmaceuticalsNASDAQ:CYNACynapsus Therapeutics Inc. (MM)
28/09/201620:27GlobeNewswire Inc.ISS Recommends Cynapsus Therapeutics Securityholders Vote for the Plan of ArrangementNASDAQ:CYNACynapsus Therapeutics Inc. (MM)
12/09/201617:08Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:CYNACynapsus Therapeutics Inc. (MM)
 Apresentando as notícias mais relevantes sobre:NASDAQ:CYNA

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
COGN3
COGNA ON
BOV
CASH3
Meliuz S.A ON
BOV
INBR32
Inter &
BOV
GOLL4
GOL PN
BOV
LUPA3
LUPATECH ON
BOV
LWSA3
LOCAWEB ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados